SDGR
Schrodinger, Inc. Health Care Pharmaceutical Preparations Russell 3000
$27.14Close
$11.07 – $32.6052-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
- Volume drying up last 10 days 27% under the 50-day average
Cautions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
17%
1wk
up 14.0%
price change
1mo
down 12.6%
price change
12-month return
up 33%
market up 11% ·
its own up 17%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 23%
year on year
EPS growth
—
latest quarter
Sales growth
up 8%
latest quarter · +9 pts
ROE
down 26%
return on equity
Free cash margin
up 5%
$12.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- FCF turned positive ($-165M → $12M)
- Revenue reaccelerating (-4% then +23%)
Trade setup
ATR%
8.0%
$2.16 a day · 2×ATR $22.81
RS
97 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
1.17
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 63.6% to 55.7%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 5, 2026
Last shock
Oct 6, 2026-11% in one session2.8× volumeno filing matched-6% since
Financials
- Gross 56%
- Net -40%
- Free cash 5%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $108.1M | $137.9M | $181.0M | $216.7M | $207.5M | $255.9M |
| Gross margin | 59% | 48% | 56% | 65% | 64% | 56% |
| Operating income | -$60.9M | -$111.4M | -$146.8M | -$177.4M | -$209.3M | -$166.9M |
| Net income | -$24.5M | -$101.2M | -$149.2M | $40.7M | -$187.1M | -$103.3M |
| Net margin | -23% | -73% | -82% | 19% | -90% | -40% |
| Earnings per share | -$0.41 | -$1.43 | -$2.10 | $0.54 | -$2.57 | -$1.41 |
| Free cash flow | $14.2M | -$77.8M | -$127.7M | -$150.1M | -$164.7M | $12.5M |
| Free cash margin | 13% | -56% | -71% | -69% | -79% | 5% |
| Cash | $202.3M | $120.3M | $90.5M | $155.3M | $147.3M | $230.5M |
| Shareholders' equity | $624.0M | $557.1M | $447.9M | $548.6M | $421.4M | $364.1M |
| Shares outstanding | 60.71m | 61.83m | 62.16m | 62.98m | — | — |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Jul 31, 2024 | Quarterly ↗ | Jun 30, 2024 | 31d |
| May 1, 2024 | Quarterly ↗ | Mar 31, 2024 | 31d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 1, 2023 | Quarterly ↗ | Sep 30, 2023 | 32d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results ↗ |
| Jun 29, 2026 | Regulation FD ↗ |
| Jun 23, 2026 | Director or officer change · Shareholder vote ↗ |
| Jun 8, 2026 | Director or officer change ↗ |
| May 20, 2026 | Director or officer change · Regulation FD ↗ |
| May 5, 2026 | Results ↗ |
| Mar 12, 2026 | Director or officer change ↗ |
| Feb 25, 2026 | Results ↗ |
| Nov 5, 2025 | Results ↗ |
| Sep 8, 2025 | Director or officer change ↗ |
| Aug 6, 2025 | Results ↗ |
| Jun 18, 2025 | Shareholder vote ↗ |